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Risk of hip, subtrochanteric, and femoral shaft fractures among 
mid and long term users of alendronate: nationwide cohort 
and nested case-control study
Bo Abrahamsen,1,2 Pia Eiken,3, 4 Daniel Prieto-Alhambra,5, 6 Richard Eastell7 
ABSTRACT
ObjeCtives
To determine the skeletal safety and efficacy of long 
term (≥10 years) alendronate use in patients with 
osteoporosis.
Design
Open register based cohort study containing two 
nested case control studies.
setting
Nationwide study of population of Denmark.
PartiCiPants
61 990 men and women aged 50-94 at the start of 
treatment, who had not previously taken alendronate, 
1996-2007.
interventiOns
Treatment with alendronate.
Main OutCOMe Measures
Incident fracture of the subtrochanteric femur or 
femoral shaft (ST/FS) or the hip. Non-fracture controls 
from the cohort were matched to fracture cases by sex, 
year of birth, and year of initiation of alendronate 
treatment. Conditional logistic regression models were 
fitted to calculate odds ratios with and without 
adjustment for comorbidity and comedications. 
Sensitivity analyses investigated subsequent 
treatment with other drugs for osteoporosis.
results
1428 participants sustained a ST/FS (incidence rate 
3.4/1000 person years, 95% confidence interval 3.2 to 
3.6), and 6784 sustained a hip fracture (16.2/1000 
person years, 15.8 to 16.6). The risk of ST/FS was lower 
with high adherence to treatment with alendronate 
(medication possession ratio (MPR, a proxy for 
compliance) >80%) compared with poor adherence 
(MPR <50%; odds ratio 0.88, 0.77 to 0.99; P=0.05). 
Multivariable adjustment attenuated this association 
(adjusted odds ratio 0.88, 0.77 to 1.01; P=0.08). The 
risk was no higher in long term users (≥10 dose years; 
0.70, 0.44 to 1.11; P=0.13) or in current compared with 
past users (0.91, 0.79 to 1.06; P=0.22). Similarly, MPR 
>80% was associated with a decreased risk of hip 
fracture (0.73, 0.68 to 0.78; P<0.001) as was longer 
term cumulative use for 5-10 dose years (0.74, 0.67 to 
0.83; P<0.001) or ≥10 dose years (0.74, 0.56 to 0.97; 
P=0.03).
COnClusiOns
These findings support an acceptable balance 
between benefit and risk with treatment with 
alendronate in terms of fracture outcomes, even for 
over 10 years of continuous use.
Introduction
The clinical management of osteoporosis has 
 progressed greatly in the past four decades with the 
introduction of potent antiresorptive drugs that sub-
stantially reduce the risk of fractures in men and 
women with osteoporosis.1  Despite the relatively low 
cost of such intervention, the treatment gap is widening 
in many areas of the world because of concerns that 
antiresorptive treatment could lead to atypical femur 
fractures2  and that this could offset the benefits of long 
term use.3  Prescription rates for bisphoshonates have 
declined by 50% in the United States4  and similar 
trends have been observed in the European Union.5 A 
recent commentary in The BMJ concluded that bisphos-
phonates could achieve at best a marginal reduction in 
the risk of hip fracture and that the risk of serious med-
ical adverse events, including atypical femur fractures, 
makes pharmacotherapy non-viable as a health strat-
egy against hip fractures.6
Fractures classified as atypical femur fractures are 
defined by a set of clinical and radiological criteria, but 
they are also confined to a distinct anatomical area. 
Atypical femur fractures are substantially transverse 
fractures originating at the lateral femoral cortex. They 
are always non-comminuted and usually accompanied 
by localised or general cortical thickening.2  These frac-
tures are a legitimate concern for prescribers and regu-
latory authorities given the short duration of the primary 
licensing trials for bisphosphonates. Trials typically 
lasted three years, with a limited proportion of partici-
pants carried forward into extension studies yielding 
a  total follow-up length of 5-10 years,7 8  providing 
WhAT IS AlReAdy knoWn on ThIS TopIC
Placebo controlled randomised clinical trials have shown a reduction in risk of hip 
fracture with alendronate treatment compared with placebo for three years in 
postmenopausal women with osteoporosis
Observational studies have suggested that atypical femur fractures involving the 
subtrochanteric femur or the femoral shaft are more common in long term users of 
bisphosphonates
WhAT ThIS STudy AddS
Long term adherent use of alendronate in excess of 10 dose years was associated 
with an adjusted 30% lower risk of hip fracture and no increase in the risk of 
fractures of the subtrochanteric femur or femoral shaft
Even if all subtrochanteric and femoral shaft fractures observed in alendronate 
users were atypical, the number remains too low to offset the benefits on hip 
fracture with long term alendronate treatment for up to 10 years
The findings support a good benefit:risk with alendronate in terms of bone health 
for over 10 years of continuous use
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 somewhat limited power to detect uncommon unex-
pected adverse events.9  The seemingly large number of 
atypical femur fractures predicted by odds ratios 
extracted from recent observational studies,10  however, 
seem to conflict with the observed slow increase and 
low overall rate of subtrochanteric and shaft fractures, 
the anatomical locations where atypical fractures 
would appear.11 12
To provide the best possible strategies for care and an 
optimum use of resources it is vitally important to rec-
ognise and verify safety alerts and, if verified, scale 
them appropriately so that clinical practice—including 
duration of osteoporosis treatment—is driven by abso-
lute rates of benefit and absolute measures of harm so 
that treatments with good safety records are not inap-
propriately withdrawn or changed to less cost effective 
or less safe alternatives. Established in 1995, the Danish 
prescription registry uniquely holds almost 20 years of 
drug exposure data for all residents in the country,13 
and this can be linked to all fracture outcomes treated 
in hospital in the same period. We used this unique real 
world data source to study the association between long 
term use of alendronate and the risk of subtrochanteric 
and femoral shaft fractures.
Methods
study design
We used a nationwide population based open registry 
cohort study, containing two nested case-control studies, 
to determine the risk of subtrochanteric and femoral 
shaft and hip fractures as a function of cumulative alen-
dronate use, time, and adherence to assess long term 
skeletal safety and efficacy.
study population and follow-up
The included population was 63 774 treatment naive 
incident users of alendronate in 1996-2007 in Denmark 
who were aged 50-94 at the time of start treatment 
(fig 1). Previous use of alendronate or other osteoporo-
sis drugs was an exclusion criterion and drug expo-
sures were tracked back to the establishment of the 
prescription registry in January 1995. We excluded 
patients who moved away from Denmark (n=1773) in 
the observation period (1996-2013) and those who 
were registered with impossible information such as a 
posthumous first prescription (n=11), leaving a study 
population of 61 990 patients exposed to alendronate. 
Patients in the cohort were followed from the start of 
treatment (that is, first prescription) until the earliest 
of death, transfer out, or end of study (31 December 
2013). As the databases are event based and capture 
hospital contacts and filled prescriptions, there were 
no identifiably missing data.
Two case-control studies were nested within the 
cohort of alendronate users. Firstly, all patients who sus-
tained a hip fracture in the study period were matched to 
up to three controls by age, sex, year of start of treat-
ment, and follow-up time. Similarly, those who experi-
enced a subtrochanteric/shaft fracture were identified as 
cases in a second case-control dataset and matched to 
up to five controls by the same four variables.
Outcomes
Outcomes were incident fractures of the hip (ICD-10 
(international classification of diseases, 10th revision) 
codes S720 and S721), subtrochanteric femur (S722), 
and the femoral shaft (S723) recorded in the Danish 
Hospital Discharge Register maintained by the Danish 
National Board of Health. Incident outcomes were 
included in the analysis irrespective of current treat-
ment status so that we could determine the association 
with strength of exposure (dose years, present user or 
not, medication possession ratio (MPR) a proxy for 
compliance).
exposures
The key exposure was pharmacy dispensations for 
alendronate (ATC (Anatomical Therapeutic Chemical) 
codes M05BA04 and M05BB03) filled in 1996-2013 as 
assessed through the National Prescription Database. 
The register contains information about the dose and 
number of tablets for all drugs dispensed irrespective 
of whether the prescription originated in hospitals, 
private clinics, or from primary care physicians. The 
medication possession ratio was calculated as the 
number of WHO defined daily doses divided by the 
length of time in days for each year of treatment, 
transferring any excess doses (>365 defined daily 
doses in a year) into the next year, where it was added 
to prescriptions filled. The dose of alendronate used in 
Denmark is always 70 mg a week—that is, a defined 
daily dose of 10 mg—as the 5 mg daily preventive dose 
for osteopenia is not licensed there. Hence, for calcu-
lations of cumulative alendronate use, we converted 
the total number of defined daily doses filled to dose 
years by dividing by 365.
All alendronate users 1 Jan 1995-31 Dec 2007 (n=81 478)
Excluded:
Age <50 (n=3215)
Age ≥95 (n=200)
Used alendronate in 1995 (n=81)
Previous osteoporosis drug (n=14 208)
Incident treatment naive alendronate users 
of correct age (n=63 774)
Nested case-control study
Excluded:
Moved away from Denmark (n=1773)
Posthumous initial prescription (n=11)
Users aged 50-94 without exclusion criteria, 
1 Jan 1996-31 Dec 2007  
(n=61 990; 6784 hip/1428 ST/SF fractures)
6784 cases of hip 
fracture with 
19 952 matched controls
1428 cases of ST/FS 
fracture with 
6825 matched controls
Fig 1 | Flow of patients using alendronate in study to 
determine effect on fractures
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Confounders
Comedications considered for multivariable adjustment 
in the case-control studies included prednisolone, 
prednisone, and proton pump inhibitors. Chronic 
comorbid conditions were identified by ICD-8 (1977-93) 
and ICD-10 (1994-) codes and included all those listed in 
the Charlson comorbidity indices.14 Previous major 
osteoporotic fractures (that is, fractures of the spine, 
forearm, humerus, hip, pelvis, and lower leg) were also 
ascertained with ICD-10 codes.
Baseline characteristics for the longitudinal cohort 
were those present at the time of the first alendronate 
prescription (cohort method), while characteristics 
(that is, confounders) adjusted for in the nested 
case-control studies were defined at the time of the frac-
ture event to adhere to case-control methods.
The study design was intended to avoid confounding 
by indication through inclusion of patients who had 
been prescribed only alendronate, a drug that is exclu-
sively used for osteoporosis and for which Danish reim-
bursement criteria require patients to have low bone 
mineral density or have experienced low trauma frac-
tures. Matching procedures were used to ensure that 
nested fracture cases and controls were of the same age 
and sex and that risk time was balanced. Residual 
unbalancing in baseline comorbid conditions, history 
of fracture before treatment, and key drug exposures 
were examined by including these as covariates in the 
conditional logistic regression analyses (see statistical 
methods).
statistical methods
We used SAS v 9.4 (SAS Institute, Cary, NC) for matching 
for the two nested case-control studies using the 
gmatch macro (Mayo Clinic, 2003). Fracture cases were 
individually matched N:1 for year of birth (maximum 
distance one year), sex, and year of initiation of alen-
dronate treatment to non-cases. Both cases and non-
cases were drawn from the cohort of alendronate users 
with no requirement to still be using alendronate as this 
is handled as an exposure variable in the subsequent 
logistic regression analysis. We used the TIME variable 
in the matching routine to ensure controls remained 
alive at the time that their fracture case experienced 
their fracture outcome. We were able to use 5:1 match-
ing in the nested case-control study of the rarer out-
come (subtrochanteric and shaft fractures) and 3:1 
matching for the hip fracture analysis. Case-control 
analyses were done with conditional logistic regression 
analysis (SPSS v 19.0) with results shown as crude and 
adjusted odds ratios with 95% confidence intervals. We 
prespecified medication possession ratio and dose 
year  cut-off points based on previous analyses of 
 observational data,15 16 where medication possession 
ratio <80% (and <50%) with alendronic acid have been 
associated with a reduced anti-fracture efficacy.
We planned sensitivity analyses in which we included 
subsequent use of osteoporosis drugs other than alen-
dronate, and subanalyses examining subtrochanteric 
and shaft fractures separately rather than combined. 
For the former, we also separately assessed inclusion of 
drugs that have (other bisphosphonates and denos-
umab) or have not (parathyroid hormone analogues, 
raloxifene, strontium ranelate) been linked to atypical 
fractures in the current literature. The rationale here 
was that the first class of drugs could add additional 
risk17  whereas the second class of drugs would either be 
neutral or, in the case of teriparatide, potentially reduce 
risk or promote healing.18
There were no post hoc or unplanned subgroup anal-
yses. We compared baseline descriptive characteristics 
with t tests and χ2 tests as appropriate, using a critical 
significance level of 5% and two sided tests throughout.
We used the risk reduction for hip fractures associ-
ated with medication possession ratio >80% to estimate 
the number of hip fractures prevented in the harm:ben-
efit calculations as numbers cannot be directly 
observed, and we preferred to use real world data rather 
than use the larger relative risk reduction found in the 
phase III trials. Number needed to treat and number 
needed to treat to harm were calculated from the 
observed event rates in separate time windows of the 
alendronate adherent cohort analysis, with 0-5 years of 
adherence as the comparator,and with the case-control 
adjusted odds ratios as an approximation for relative 
risk reduction (where odds ratios <1) or increase (where 
odds ratios >1) as a function of duration of treatment.19 
Number needed to treat to harm is the same metric 
based on excess adverse events for those analyses 
where the adjusted odds ratios was >1, regardless of sig-
nificance, to provide a “worst case scenario” (none of 
the obtained odds ratios were >1 and significant). No 
power calculation was performed as we included all eli-
gible patient records.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for recruitment, design or implemen-
tation of the study. No patients were asked to advise on 
interpretation or writing up of results. Patient charities 
will be involved in the dissemination of our findings to 
relevant audiences in the UK (via the National Osteopo-
rosis Society) and Denmark (via the Danish Osteoporo-
sis Society).
Results
The 61 990 alendronate users who made up the study 
cohort were followed for fracture outcomes for a 
median follow-up time of 6.9 years (range 0-17.9, inter-
quartile range 4.1-9.0), making a total of 418 430 person 
years. During this time 1428/61 990 (2.3%; incidence 
rate 3.4/1000 person years, 95% confidence interval 3.2 
to 3.6) sustained a subtrochanteric and femoral shaft 
 fracture, and 6784/61 990 (10.9%; 16.2/1000 person 
years, 15.8 to 16.6) sustained a hip fracture. These con-
stituted the cases for the two nested case-control anal-
yses (fig 1). The mean age at subtrochanteric and 
femoral shaft fracture was 75 (SD 9.5) and at hip frac-
ture was 76.5 (SD 8.9). The cumulative incidence of the 
two types of fracture is shown in fig 2. Table 1  shows 
the baseline characteristics for the study cohort 
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(at start of treatment). Table 2 shows clinical character-
istics for both matched nested case-control studies.
Cohort study of long term rates of fracture in 
adherent alendronate users
Out of the 61 990 alendronate users who made up the 
cohort, 18 242 (29.4%) completed five years of treatment, 
with a medication possession ratio of 80% or more, 
2465 (4.0%) completed 10 years, and fewer than 1000 
patients completed 14 years or more. For the first 10 
years, rates of hip fracture declined from an initial 
36.2/1000 person years in the first year of treatment to a 
stable 10-15 per 1000 patient years (fig 3), while the total 
rate of subtrochanteric and femoral shaft fractures 
remained stable at 2.7-4.6/1000 patient years.
Case control study of subtrochanteric and shaft 
fractures
Table 2 shows the characteristics of the 1428 patients 
who experienced a subtrochanteric and femoral shaft 
fracture and their 6825 age and sex matched (5:1) cohort 
controls (alendronate users who did not experience the 
outcome of interest). Briefly, those with subtrochanteric 
and femoral shaft fracture had a higher Charlson 
comorbidity index, were more likely to have a history of 
major osteoporotic fractures, and have diabetes, 
chronic pulmonary disease, and previous myocardial 
infarction. The frequency of use of proton pump inhibi-
tors was also higher among cases.
Conditional logistic regression analysis (table 3) 
showed a reduced risk of subtrochanteric and femoral 
shaft fracture in highly adherent users (medication 
possession ratio >80%) compared with poor adher-
ers (<50%, reference category; odds ratio 0.88, 
95%   confidence interval 0.77 to 0.99; P=0.05). This 
changed, however, when we adjusted for comorbid 
conditions (adjusted odds ratios 0.90, 0.78 to 1.03; 
table 1 | baseline descriptive characteristics for full 
cohort at start of treatment with alendronate for 
osteoporosis. Figures are numbers (percentage) of 
patients unless specified otherwise
Full alendronate 
cohort (n=61 990)
Mean (SD) age (years) 72.1 (10.0)
Women 51 558 (83.2)
Charlson index:
 0 30 150 (48.6)
 1 4247 (6.9)
 2 13 953 (22.5)
 ≥3 13 640 (22.0)
Main comorbid conditions:
 Any fracture
 Major osteoporotic fracture 19 261 (31.1)
 Fracture of pelvis, femur, or lower leg
 Diabetes 3085 (5.0)
 Chronic kidney disease 449 (0.7)
 Chronic pulmonary disease 11 942 (19.3)
 Previous myocardial infarction 3998 (6.4)
Drug history:
 Prednisolone in past year 15 377 (24.8)
Years of treatment
Cu
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0 5 10 15
No of patients 43 562 10 287 1413
0
0.2
0.4
Hip fracture
ST/FS fracture
Fig 2 | Kaplan-Meier cumulative incidence plot of hip 
fracture and subtrochanteric and femoral shaft fracture 
(st/Fs) as function of time for all people treated with 
alendronate irrespective of adherence
table 2 | Comorbid conditions and comedications at time of event in two nested case-control studies. Differences in comorbid conditions and 
comedications between outcome groups, combined with data on degree of alendronate exposure, drive conditional logistic regression analyses in 
subsequent tables. Figures are numbers (percentage) of patients unless specified otherwise
subtrochanteric and femoral shaft fracture Hip fracture
Cases (n=1428) Controls (n=6825) P value Cases (n=6784) Controls (n=19 952) P value
Mean (SD) age (years) 79.6 (9.4) 79.7 (9.4) NA* 80.2 (8.9) 80.1 (8.8) NA*
Women 1258 (88.1) 6056 (88.7) NA* 5980 (88.1) 17 605 (88.1) NA*
Charlson index:
 0 409 (28.6) 2530 (37.1)
<0.001
2092 (30.8) 7504 (37.6)
<0.001
 1 102 (7.1) 442 (6.5) 514 (7.6) 1475 (7.4)
 2 323 (22.6) 1593 (23.3) 1485 (21.9) 4573 (22.9)
 ≥3 594 (41.6) 2260 (33.1) 2693 (39.7) 6400 (32.1)
Main comorbid conditions:
 Any fracture 1091 (76.4) 3447 (50.5) <0.001 4287 (63.4) 9061 (45.9) <0.001
 Major osteoporotic fracture 987 (69.1) 2967 (43.5) <0.001 3778 (55.8) 7709 (39.1) <0.001
 Fracture of pelvis, femur, or lower leg 364 (25.5) 1034 (15.2) <0.001 1260 (18.6) 2547 (12.9) <0.001
 Diabetes 125 (8.8) 400 (5.9) <0.001 496 (7.3) 1204 (6.1) <0.001
 Chronic kidney disease 25 (1.8) 74 (1.1) 0.04 125 (1.8) 248 (1.3) <0001
 Chronic pulmonary disease 325 (22.8) 1382 (20.2) 0.03 1497 (22.1) 4001 (20.3) 0.001
 Previous myocardial infarction 144 (10.1) 541 (7.9) 0.008 648 (9.6) 1726 (8.7) 0.04
Drug history (in past year):
 Prednisolone 252 (17.6) 1336 (19.6) 0.10 1255 (18.5) 4146 (20.8) <0.001
 Proton pump inhibitors 483 (33.8) 1948 (28.5) <0.001 2226 (32.8) 5488 (27.5) <0.001
 Thiazides 350 (24.5) 1751 (25.7) 0.38 1762 (26.0) 5187 (26.0) 0.97
*Age and sex matched analysis, P values not calculated.
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P=0.11). We did not find any association with cumula-
tive use of alendronate (adjusted 0.72, 0.45 to 1.14; 
P=0.16, for users of ≥10 dose years) or with current use 
compared with past use (0.92, 0.79 to 1.07; P=0.27). 
Sensitivity analyses in which subsequent use of other 
osteoporosis drugs including potent antiresorptives 
such as denosumab did not modify these findings. 
The risk of subtrochanteric and femoral shaft frac-
tures was significantly higher in patients with comor-
bid conditions, including diabetes, and in patients 
who filled prescriptions for proton pump inhibitors. 
Use of more than 10 dose years of alendronate was 
associated with a decreased risk (0.43, 0.22 to 0.83; 
P=0.01; fig 4) for subtrochanteric femur fractures but 
no reduction in the risk of shaft fractures (1.16, 0.60 to 
2.23; P=0.66).
nested case-control study of hip fractures
Conditional logistic regression (table 4) in the nested 
case control study of the 6784 users who experienced a 
hip fracture in the follow-up period, matched by age 
and sex to 19 952 users who did not experience hip frac-
tures, showed a reduced risk of hip fracture in current 
compared with past users (adjusted odds ratios 0.70, 
95% confidence interval 0.65 to 0.77; P<0.001). Optimal 
compliance (users with medication possession ratio 
>80%; 0.73, 0.69 to 0.79; P<0.001) as well as cumulative 
use for 5-10 dose years (0.74, 0.67 to 0.83; P<0.001) or 
>10 dose years (0.74, 0.55 to 0.97; P=0.03) were 
 associated with a reduced risk of hip fracture.  Sensitivity 
analyses that excluded switchers to other osteoporosis 
drugs did not alter the findings. The risk was higher if 
patients had previous major osteoporotic fractures, 
used proton pump inhibitors, or had comorbid condi-
tions such as diabetes or kidney disease.
long term harm:benefit model
In each year, the upper 95% confidence limit for subtro-
chanteric and femoral shaft fractures was lower than 
the observed rate of hip fractures in up to 13 years of 
alendronate adherence (fig 3). Table 5 summarises the 
fracture rates during 0-5 years, 5-10 years, and ≥10 years 
of alendronate adherence. Combination of these 
observed event rates of subtrochanteric and femoral 
shaft and hip fractures and the odds ratios adjusted for 
confounding from the nested case control studies 
yielded a number needed to treat for hip fractures of 38 
people treated for an additional five years to prevent 
one hip fracture after both ≥5 and ≥10 years of alendro-
nate adherence, compared with people with less than 
five years of adherence. For subtrochanteric and femo-
ral shaft fractures, we found a number needed to treat 
to harm of 1449 people treated for an additional five 
years to account for one additional subtrochanteric and 
femoral shaft fracture in the 5-10 year scenario. The ≥10 
year scenario yielded a risk reduction compared with 
less than five years of alendronate adherence and a 
number needed to treat of 193 people treated for an 
additional five years to avoid one subtrochanteric and 
femoral shaft fracture. Both time scenarios indicated an 
overall lower fracture burden at the hip and femur with 
long alendronate adherence compared with less than 
five years of adherence.
discussion
Principal findings
This study provides real world data on the incidence 
rates of subtrochanteric and diaphyseal femur frac-
tures with verified long term adherence to alendro-
nate, a subset of femur fractures that captures the total 
rate of atypical and typical femur fractures to be offset 
against hip fractures prevented. In addition, two 
nested case control studies explored risk factors for 
subtrochanteric and femoral shaft and hip fractures, 
respectively, and showed that while use of alendro-
nate in excess of 10 dose years was associated with a 
30% lower risk of hip fracture, there was no increase 
in the risk of fractures of the subtrochanteric femur or 
femoral shaft. It is important to appreciate that the two 
case-control studies incorporate an adjustment for 
confounders such as previous fractures, diabetes, and 
proton pump inhibitors that are not considered in the 
cohort analysis. Hence the purpose of the cohort anal-
ysis is to provide absolute fracture rates for harm:ben-
efit modelling, whereas the nested case-control 
studies are optimal for estimating the influence of 
adherence (medication possession ratio) and cumula-
tive use (dose years) on the risk of fractures when we 
take into account other patient factors that might be 
unbalanced between fracture cases and matched 
non-fracture controls.
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Fig 3 | Fracture rates and 95% confidence intervals per 1000 patient years for hip fractures 
and subtrochanteric and femoral shaft fractures in highly adherent alendronate users 
(medication possession ratio >80%). Hip fractures prevented calculated based on Or of 
0.70 as derived from nested case-control analyses (see text for details)
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From a pharmacoepidemiological point of view we 
then proceeded to assume a worst case scenario in which 
all subtrochanteric and femoral shaft fractures observed 
were considered atypical and attributable to bisphospho-
nate treatment—assuming a rate of zero in the background 
population—and applying the upper 95% confidence 
limit in the harm:benefit models rather than the observed 
rates. With this extreme scenario there was still a net sav-
ing in fractures at the hip and femur for up to 10 years of 
treatment with high  adherence.
table 3 | nested case-control analysis of exposure to drug treatment and comorbid conditions as predictor of subtrochanteric or shaft fractures of femur 
in treatment naive adults initially starting alendronate in Denmark. table summarises several multivariate conditional logistic regression analyses of 
exposure in terms of current user status, adherence, or number of dose years
no (%) of 
patients
Or (95% Ci) for subtrochanteric and femoral shaft fracture
unadjusted adjusted*
alendronate (users switching to other osteoporosis drugs considered no longer exposed)
User status:
 Past user (≥1 year before) 2193 (26.6) Reference —
 Recent user (<1 year before) 971 (11.8) 1.04 (0.85 to 1.28), P=0.69 1.00 (0.82 to 1.25), P=0.93
 Current user 5089 (61.7) 0.92 (0.80 to 1.06), P=0.24 0.92 (0.79 to 1.07), P=0.27
Medication possession ratio:
 <50% 2520 (30.5) Reference
 50-80% 882 (10.7) 1.08 (0.89 to 1.32), P=0.45 1.04 (0.84 to 1.27), P=0.74
 >80% 4851 (58.8) 0.88 (0.77 to 0.99), P=0.05 0.90 (0.78 to 1.03), P=0.11
Dose years:
 <5 6297 (76.3) Reference
 5-<10 1712 (20.7) 1.02 (0.85 to 1.22), P=0.88 1.05 (0.87 to 1.28), P=0.58
 ≥10 244 (3.0) 0.70 (0.45 to 1.09), P=0.11 0.72 (0.45 to 1.14), P=0.16
Sensitivity analysis:
 Dose years: —
  <3 4923 (59.3) 0.95 (0.79 to 1.15), P=0.62 0.94 (0.77 to 1.15), P=0.55
  3-<5 1374 (16.6) Reference
  ≥5-<10 1712 (20.7) 0.98 (0.78 to 1.23), P=0.86 0.99 (0.79 to 1.26), P=0.96
  >10 244 (3.0) 0.67 (0.42 to 1.07), P=0.09 0.67 (0.41 to 1.08), P=0.10
alendronate (users switching to other osteoporosis drugs removed from analysis)
User status:
 Past user (≥1 year before) 1448 (20.2) Reference —
 Recent user (<1 year before) 817 (11.4) 1.04 (0.82 to 1.32), P=0.73 1.00 (0.79 to 1.29), P=0.96
 Current user 4917 (68.5) 0.96 (0.81 to 1.13), P=0.60 0.94 (0.79 to 1.13), P=0.51
Medication possession ratio:
 <50% 1748 (24.3) Reference —
 50-80% 701 (9.8) 1.00 (0.79 to 1.26), P=0.99 0.93 (0.73 to 1.19), P=0.57
 >80% 4733 (65.9) 0.88 (0.76 to 1.03), P=0.11 0.88 (0.75 to 1.04), P=0.13
Dose years:
 <5 5388 (75.0) Reference —
 5-<10 1571 (21.9) 1.05 (0.85 to 1.31), P=0.63 1.06 (0.84 to 1.33), P=0.63
 ≥10 223 (3.1) 0.73 (0.42 to 1.27), P=0.25 0.86 (9.49 to 1.51), P=0.59
Sensitivity analysis:
 Dose years:
  <3 4141 (57.7) 0.98 (0.78 to 1.22), P=0.82 0.94 (0.74 to 1.18), P=0.58
  3-<5 1247 (17.4) Reference —
  ≥5-<10 1571 (21.9) 1.04 (0.80 to 1.35), P=0.79 1.01 (0.77 to 1.34), P=0.93
  >10 223 (3.1) 0.71 (0.41 to 1.25), P=0.24 0.82 (0.45 to 1.47), P=0.50
Comorbid conditions and comedications
Major osteoporotic fracture 3954 (47.9) 3.09 (2.72 to 3.51), P<0.001 3.05 (2.68 to 3.47), P<0.001
Fracture of pelvis, femur or lower leg 1398 (16.9) 1.90 (1.65 to 2.18), P<0.001 1.55 (1.34 to 1.79), P<0.001
Fractures, other 361 (4.4) 1.50 (1.17 to 1.93), P=0.002 1.15 (0.88 to 1.51), P=0.29
Diabetes 525 (6.4) 1.55 (1.26 to 1.91), P<0.001 1.41 (1.13 to 1.76), P=0.002
Chronic kidney disease 99 (1.2) 1.64 (1.03 to 2.60), P=0.04 1.44 (0.89 to 2.35), P=0.14
Chronic pulmonary disease 1707 (20.7) 1.16 (1.01 to 1.34), P=0.047 1.16 (0.99 to 1.34), P=0.06
Previous myocardial infarction 685 (8.3) 1.32 (1.08 to 1.60), P=0.006 1.23 (0.99 to 1.51), P=0.05
Prednisolone in past year 1588 (19.2) 0.87 (0.75 to 1.01), P=0.07 0.93 (0.79 to 1.09), P=0.35
Proton pump inhibitors in past year 2431 (29.5) 1.29 (1.14 to 1.46), P<0.001 1.20 (1.06 to 1.37), P=0.005
Thiazides in past year 2101 (25.5) 0.93 (0.81 to 1.07), P=0.30 0.97 (0.85 to 1.12), P=0.71
*Adjusted for comorbid diabetes, chronic kidney disease, chronic pulmonary disease, and previous myocardial infarction, and use in past year of prednisolone, proton pump inhibitors, and thiazides.
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Comparison with other/previous studies
Atypical femur fractures are thought to be linked to 
impaired properties of bone material with hyperminer-
alisation, loss of flexibility, increased hardness, and 
loss of toughness. It is unknown if there is a genetic sus-
ceptibility to such fractures, but the risk is clearly 
higher in people of South East Asian origin,20  and sev-
eral groups have found links to femur shape and hip 
geometry.21-23  It is not clear if every patient treated for 
osteoporosis could develop atypical femur fractures or 
if only a small minority of patients could be at risk so 
identification of strong clinical risk factors could be 
helpful. Previous studies have shown that the use of 
proton pump inhibitors and diabetes mellitus are asso-
ciated with subtrochanteric and shaft fracture,24-26 and 
we confirmed that they were strong risk factors in our 
study. A reduced risk of fracture in prednisolone users 
was seen only in the unadjusted analyses but as it was 
attenuated in the multivariable models this observation 
was probably caused by confounding.
Recent reports from Sweden indicate that the relative 
risk of atypical femur fractures is increased 126-fold (11 
per 10 000 patient years) after as little as four years of 
exposure to bisphosphonates.10 The rate of classic hip 
fractures was almost identical among bisphosphonate 
users in the Swedish analysis and in our study, at about 
1500 per 10 000 person years. We observed only 46 sub-
trochanteric and femoral shaft fractures per 10 000 per-
son years in the 10th year of alendronate treatment, but 
no risk increase with time or cumulative dose whether 
or not we adjusted for comorbid conditions and comed-
ications. Because of the extremely low rate of atypical 
femur fractures in the general population (0.09 per 
10 000 reported for Sweden) the risk of atypical femur 
fractures could increase by more than 100-fold in four 
years of bisphosphonate use with no impact on the bur-
den of femoral and hip fracture. The rate of hip frac-
tures of 1500 per 10 000 per year in Danish and Swedish 
bisphosphonate users is almost 1700 times higher than 
the rate of atypical femur fractures in non-bisphospho-
nate users reported from Sweden.
Our study provides reassurance that the total risk of 
subtrochanteric and femoral shaft fractures does not 
increase over the first 10 years of high adherence to 
alendronate in Danish adults with osteoporosis, 
implying that increases in atypical femur fractures are 
offset by decreases of at least the same size in the risk 
of non-atypical subtrochanteric and femoral shaft 
fractures. Atypical femur fractures are not undermin-
ing the benefits on hip fracture; they are not even dis-
cernible as an increase in subtrochanteric and femoral 
shaft fractures. Though we observed an increase in the 
rates of both subtrochanteric and femoral shaft frac-
tures and hip fractures after 13 years or more, the 
case-control analysis suggests that this might not 
be indicative of a change in treatment effect but of a 
more adverse risk factor profile in those with long term 
adherent use.
strengths and limitations
The key limitation of the present study is that radio-
graphs were not available so the absolute harm rates 
reported here are inflated by inclusion of non-atypical 
subtrochanteric fractures and shaft fractures. The 
proportion of subtrochanteric and femoral shaft frac-
tures among bisphosphonate users accounted for by 
atypical femur fractures varies somewhat between 
studies. The updated report from Sweden10  identified 
172 atypical femur fractures among 5475 subtrochan-
teric and femoral shaft fractures (3.1%), though 4218 
fractures were classed as irrelevant on radiological 
review, either because of prostheses or a condylar or 
trochanteric location, despite the ICD-10 coding 
applied, bringing the number of atypical femur frac-
tures among true subtrochanteric and femoral shaft 
fractures in a mechanically unaltered femur to 13.4%. 
The Kaiser California study27  identified 142 atypical 
femur fractures (3.5%) among 4036 subtrochanteric 
and femoral shaft fractures. By contrast, the Kaiser 
Northwest study reported that 38% of femoral shaft 
fractures and 8.6% of reviewed femur radiographs ful-
filled the criteria for classification as atypical femur 
fractures.28
Though use of drug adherence and cumulative dose 
as the driver for the analysis is a classic method in phar-
macoepidemiology, it is important to recognise the lim-
itations. Patients who adhere to treatment might differ 
on unmeasured confounders—such as education, nutri-
tion, or exercise habits—from those who do not adhere 
to treatment. This would lead to residual confounding, 
which could bias our findings; such issues, however, 
are present in all observational studies and can be 
resolved only in long term randomised controlled trials. 
Also, given current recommendations about the dura-
tion of treatment with bisphosphonates, patients who 
receive treatment for the longest might do so because 
they have strong risk factors for fracture, and this could 
lead to a higher risk of fracture after 5-10 years of treat-
ment. The opposite might also be true, as patients who 
adhere to treatment might be risk aware and follow 
other recommendations (that is, “healthy adherers”) 
commonly given together with the prescription of 
Alendronate dose years
Femoral sha
<5
5-10 
≥10
Subtrochanteric
<5
5-10
≥10
Hip
<5
5-10
≥10
OR (95%CI)
Reference
1.04 (0.77 to 1.42)
1.16 (0.60 to 2.23)
Reference
1.04 (0.82 to 1.31)
0.43 (0.22 to 0.83)
Reference
0.75 (0.67 to 0.83)
0.74 (0.56 to 0.97)
OR (95%CI)
0.00 0.50 1.00 1.50 2.00
Reduced risk Increased risk 
Fig 4 | subanalysis of femoral shaft fractures, 
subtrochanteric fractures, and hip fractures. nested 
case-control analysis adjusted for covariates in tables 2 
and 3
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anti-osteoporosis drugs (for example, physical activity, 
lifestyle modification, dietary calcium intake, etc). 
Excess mortality in those with the lowest bone mineral 
density and highest fracture risk might contribute as 
well. It is important to be aware that unlike the 
case-control analyses, the rates shown in fig 3 are not 
adjusted or standardised for age, sex, or comorbidity. 
An additional limitation of our data is the lack of infor-
mation on use of calcium/vitamin D supplements, as 
these are almost exclusively purchased over the counter 
in Denmark, making it impossible for us to study them 
from prescription data.
table 4 | nested case-control analysis of exposure to drug treatment and comorbid conditions as predictor of hip fractures in treatment naive adults 
initially starting alendronate in Denmark. table summarises several multivariate conditional logistic regression analyses examining exposure in terms 
of current user status, adherence, or number of dose years
no (%) of 
patients
Or (95% Ci) for hip fracture
unadjusted adjusted*
alendronate (users switching to other osteoporosis drugs considered no longer exposed)
User status:
 Past user (≥1 year before) 6297 (23.6) Reference —
 Recent user (<1 year before) 11 592 (43.4) 0.78 (0.73 to 0.84), P<0.001 0.79 (0.74 to 0.86), P<0.001
 Current user 8847 (33.1) 0.70 (0.65 to 0.76), P<0.001 0.70 (0.65 to 0.77), P<0.001
Medication possession ratio:
 <50% 7125 (26.6) Reference —
 50-80% 2838 (10.6) 0.99 (0.90 to 1.09), P=0.85 0.98 (0.89 to 1.08), P=0.65
 >80% 16 773 (62.7) 0.72 (0.68 to 0.77), P<0.001 0.73 (0.69 to 0.79), P<0.001
Dose years:
 <5 22 220 (83.1) Reference —
 ≥5-<10 4091 (15.3) 0.74 (0.67 to 0.82), P<0.001 0.74 (0.67 to 0.83), P<0.001
 ≥10 425 (1.6) 0.74 (0.56 to 0.97), P=0.03 0.74 (0.55 to 0.97), P=0.03
Sensitivity analysis:
 Dose years:
  <3 18 396 (68.8) 1.27 (1.15 to 1.40), P<0.001 1.24 (1.13 to 1.38), P<0.001
  ≥3-<5 3767 (14.1) Reference —
  ≥5-<10 4091 (15.3) 0.87 (0.77 to 0.99), P=0.03 0.87 (0.77 to 0.99), P=0.04
  ≥10 425 (1.6) 0.88 (0.67 to 1.17), P=0.39 0.86 (0.65 to 1.15), P=0.32
alendronate (users switching to other osteoporosis drugs removed from analysis)
User status:
 Past user (≥1 year before) 4238 (17.8) Reference —
 Recent user (<1 year before) 10 907 (45.8) 0.74 (0.67 to 0.80), P<0.001 0.74 (0.68 to 0.81), P<0.001
 Current user 8661 (36.4) 0.66 (0.60 to 0.72), P<0.001 0.65 (0.59 to 0.72), P<0.001
Medication possession ratio:
 <50% 5020 (21.1) Reference —
 50-80% 2372 (10.0) 0.97 (0.87 to 1.09), P=0.64 0.96 (0.85 to 1.08), P=0.47
 >80% 16 414 (68.9) 0.69 (0.64 to 0.74), P<0.001 0.70 (0.64 to 0.75), P<0.001
Dose years:
 <5 19 619 (82.4) Reference —
 ≥5-<10 3793 (15.9) 0.68 (0.60 to 0.77), P<0.001 0.69 (0.61 to 0.78), P<0.001
 ≥10 394 (1.7) 0.64 (0.46 to 0.89), P=0.01 0.63 (0.45 to 0.88), P=0.007
Sensitivity analysis:
 Dose years:
  <3 16 168 (67.9) 1.30 (1.15 to 1.45), P<0.001 1.26 (1.12 to 1.42), P<0.001
  ≥3-<5 3451 (14.5) Reference —
  ≥5-<10 3793 (15.9) 0.80 (0.70 to 0.93), P=0.002 0.80 (0.69 to 0.92), P=0.002
  ≥10 394 (1.7) 0.81 (0.58 to 1.13), P=0.22 0.75 (0.53 to 1.06), P=0.10
Comorbid conditions and comedications
Major osteoporotic fracture 11 487 (43) 2.01 (1.89 to 2.13), P<0.001 1.99 (1.88 to 2.11), P<0.001
Fracture of pelvis femur or lower leg 3807 (14.2) 1.55 (1.44 to 1.66), P<0.001 1.37 (1.27 to 1.48), P<0.001
Fractures other 1050 (3.9) 1.68 (1.48 to 1.92), P<0.001 1.41 (1.24 to 1.62), P<0.001
Diabetes 1700 (6.4) 1.22 (1.09 to 1.36), P<0.001 1.17 (1.05 to 1.31), P<0.001
Chronic kidney disease 373 (1.4) 1.49 (1.19 to 1.85), P<0.001 1.35 (1.08 to 1.69), P<0.001
Chronic pulmonary disease 5498 (20.6) 1.13 (1.06 to 1.21), P<0.001 1.13 (1.05 to 1.21), P<0.001
Previous myocardial infarction 2374 (8.9) 1.11 (1.01 to 1.22), P=0.03 1.04 (0.95 to 1.15), P=0.39
Prednisolone in past year 5401 (20.2) 0.87 (0.81 to 0.93), P<0.001 0.87 (0.81 to 0.94), P<0.001
Proton pump inhibitors in past year 7714 (28.9) 1.29 (1.22 to 1.37), P<0.001 1.25 (1.18 to 1.33), P<0.001
Thiazides in past year 6949 (26.0) 0.99 (0.94 to 1.07), P=0.98 1.00 (0.94 to 1.07), P=0.94
*Adjusted for comorbid diabetes, chronic kidney disease, chronic pulmonary disease, and previous myocardial infarction, and use in past year of prednisolone, proton pump inhibitors, and thiazides.
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Our study population was almost exclusively North 
European, and the results might not apply to other eth-
nic groups, particularly to patients of South Asian heri-
tage who might be at particular risk of atypical femur 
fractures.20  Also, we focused on subtrochanteric/shaft 
femoral fractures but did not study the potential 
increase in risk of another relevant potential bone 
undesired effect: osteonecrosis of the jaw. Finally, 
though we provide quantitative data on the benefits and 
risks of treatment in terms of burden of femur fracture, 
we did not account for the high morbidity associated 
with atypical fractures, which can be high and even 
exceed that of hip fracture. Recent research, however, 
has shown that the mortality associated with atypical 
femoral fractures is lower than previously assumed29 
and clearly lower than that after a hip fracture. More 
data are therefore needed for an accurate evaluation of 
the impact of such fractures on patients’ morbidity and 
mortality.30
The present type of study is more informative for 
deriving benefit and harm rates than for disentangling 
the mechanisms underlying atypical femur fractures. 
The most important strength of the study is the quality 
and duration of drug exposure data, which allows 
researchers to work with almost two decades of drug 
prescription data, encompassing the early years of 
alendronate becoming established as a therapeutic 
option in Denmark. We used an elaborate user only 
study design to eliminate drug channelling bias and 
embedded two case control studies in a longitudinal 
open cohort study of alendronate use to achieve opti-
mum statistical power for this rare fracture outcome. By 
using nested case-control studies we sought to over-
come the colinearity challenge that would have been 
posed in a cohort study with Cox proportional hazards 
models incorporating a time dependent covariate 
because there would be strong colinearity of time and 
cumulative dose. Moreover, if risks change abruptly 
with duration of use then the proportional hazards 
assumption would not hold. The nested case-control 
setup allowed us to enter strength of alendronate expo-
sure in several conventional ways used in pharmacoep-
idemiology (refill compliance, dose years, and present 
versus past use) to identify a risk association if one was 
indeed present. The analysis did not only recapture 
those risk factors already known to predict fractures in 
other studies, it also showed risk reductions for hip 
fractures consistent with those observed in other real 
world settings.15 31
Regarding the potential benefits of treatment with 
bisphosphonates, our data are consistent with findings 
of previous systematic reviews of randomised con-
trolled trials: a Cochrane review published in 2008 
reported on a 40% relative risk reduction of hip fracture 
after up to four years of treatment with alendronic acid.32 
This protective effect was stronger (over 50% risk 
reduction) in secondary fracture prevention. In our 
study, in which almost one in three patients received 
secondary prevention, we observed an overall almost 
30% reduction on risk of hip fracture associated with 
good compliance. These protective effects extended for 
up to in excess of 10 years, complementing previous 
randomised studies included in the Cochranesystem-
atic review32 with long term (observational) effective-
ness data.
There is an important difference between the present 
case-control analyses and those that have been con-
ducted in the context of most radiology review studies 
of atypical femur fractures. Our analyses used a classic 
case-control design in which patients with an outcome 
were compared with similar patients (for instance, 
users of the same drug of same age, sex, and who 
started treatment in the same year) without this out-
come to identify factors associated with the risk of 
developing the outcome in question. Previous case- 
control studies have relied on patients with other 
table 5 | Fracture rates as function of duration of treatment with alendronate in patients with medication possession 
ratio of 80% or more
treatment duration (years)
0-5 5-10 >10
subtrochanteric and femoral shaft fracture
No of patients 566 157 19
Patient years 163 590 49 399 4600
Incidence rate* (per 1000 person years) 3.45 (3.18 to 3.76) 3.18 (2.70 to 3.72) 4.13 (2.49 to 6.45)
Case-control odds ratios (table 3) Reference 1.04 0.70
Number needed to treat† Reference — 193
Number needed to harm† Reference 1449 —
Hip fracture
No of patients 3289 562 66
Patient years 160 556 47 269 4362
Incidence rate* (per 1000 person years) 20.48 (19.79 to 21.20) 11.89 (10.92 to 12.91) 15.13 (11.70 to 19.25)
Case-control odds ratios (table 4) Reference 0.74 0.74
Number needed to treat† Reference 38 38
Number needed to harm† Reference — —
*Incidence rate for comparison based on observed absolute event rates. Lower incidence rate does not necessarily imply lower odds ratios as patients 
with different duration of use might differ on risk characteristics.
†Number needed to treat and number needed to harm express number of patients who must be treated for another additional five years to prevent (number 
needed to treat) or add (number needed to harm) one additional fracture respectively. Comparator is treatment for 0-5 years. Case-control odds ratio 
that contribute to calculation of these is age and sex matched metric adjusted for comorbid conditions and comedications (see tables 2 and 3 for details).
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 femoral fractures as controls for patients with atypical 
femur fractures.24 28 33-35 This approach produces an 
odds ratio that measures the likelihood that patients 
who sustain fractures of the femur do so in the form of 
atypical fractures, with an external validity that extends 
to patients with hip and femur fracture alone and not to 
bisphosphonate users in general. This is akin to identi-
fying risk factors for breast cancer solely from a case 
comparison with women with colon cancer.
Conclusions and policy implications
In summary, the present nationwide register based 
cohort and case-control studies with long term adher-
ence data found that use of alendronate in excess of 10 
dose years was associated with a confounder adjusted 
30% lower risk of hip fracture and no increase in the 
risk of fractures of the subtrochanteric femur and femo-
ral shaft. In addition, we have shown that even in the 
worst case scenario (assuming 100% of subtrochanteric 
and femoral shaft fractures are atypical and secondary 
to bisphosphonate use and making no allowance for 
the higher prevalence of comorbid conditions in these 
patients) the number of atypical femur fractures 
remains too low to offset the benefits on hip fracture in 
patients with long term alendronate use up to 10 years. 
Furthermore, realistic comorbidity adjusted number 
needed to treat to harm and number needed to treat sce-
narios suggested that use of alendronate for more than 
10 years remains favourable at the femur and hip. Long 
term exposure data linked to radiologically adjudicated 
fracture outcomes are recommended to accurately 
determine the true, and possibly even lower, rate of 
atypical femur fractures.
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